September 25, 2017 – By test
Analysts expect Colliers International Group Inc (NASDAQ:CIGI) to report $0.26 EPS on October, 27.They anticipate $0.13 EPS change or 33.33% from last quarter’s $0.39 EPS. CIGI’s profit would be $9.74M giving it 47.50 P/E if the $0.26 EPS is correct. After having $0.73 EPS previously, Colliers International Group Inc’s analysts see -64.38% EPS growth. About 46,673 shares traded. Colliers International Group Inc (NASDAQ:CIGI) has risen 36.16% since September 25, 2016 and is uptrending. It has outperformed by 19.46% the S&P500.
Actinium Pharmaceuticals Incorporated (NYSEMKT:ATNM) had a decrease of 16.03% in short interest. ATNM’s SI was 1.47M shares in September as released by FINRA. Its down 16.03% from 1.75M shares previously. With 357,700 avg volume, 4 days are for Actinium Pharmaceuticals Incorporated (NYSEMKT:ATNM)’s short sellers to cover ATNM’s short positions. About 195,337 shares traded. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has declined 15.34% since September 25, 2016 and is downtrending. It has underperformed by 32.04% the S&P500.
Among 4 analysts covering Colliers (NASDAQ:CIGI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Colliers had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, January 31 by Raymond James. On Tuesday, August 1 the stock rating was maintained by BMO Capital Markets with “Buy”. The firm earned “Buy” rating on Monday, June 26 by RBC Capital Markets. The stock of Colliers International Group Inc (NASDAQ:CIGI) has “Outperform” rating given on Wednesday, October 28 by RBC Capital Markets. BMO Capital Markets maintained the stock with “Buy” rating in Wednesday, June 28 report. IBC upgraded the stock to “Sector Outperform” rating in Thursday, February 16 report. RBC Capital Markets maintained the shares of CIGI in report on Thursday, August 6 with “Outperform” rating. RBC Capital Markets maintained Colliers International Group Inc (NASDAQ:CIGI) on Monday, February 8 with “Sector Perform” rating. The rating was maintained by RBC Capital Markets on Tuesday, August 1 with “Buy”. The rating was initiated by RBC Capital Markets on Wednesday, June 15 with “Outperform”.
Colliers International Group Inc. is engaged in the provision of commercial real estate services. The company has market cap of $1.85 billion. The Firm offers services, including outsourcing and advisory services, lease brokerage and sales brokerage. It has a 29.75 P/E ratio. The Company’s divisions include Americas; Europe, Middle East and Africa ; Asia Pacific, and Corporate.
Among 2 analysts covering Actinum Pharma (NYSEMKT:ATNM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Actinum Pharma had 2 analyst reports since October 15, 2015 according to SRatingsIntel. Roth Capital initiated it with “Buy” rating and $5 target in Thursday, August 25 report. As per Thursday, October 15, the company rating was initiated by FBR Capital.
Since June 15, 2017, it had 3 buys, and 0 insider sales for $18,370 activity. Another trade for 3,500 shares valued at $4,095 was bought by O’Loughlin Steve. Shares for $5,550 were bought by Berger Mark Stanley. Shares for $8,725 were bought by SETH SANDESH on Thursday, June 15.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm engaged in developing cancer treatments. The company has market cap of $48.00 million. The Firm is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. It currently has negative earnings. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.